Takeda Pharmaceutical Company Statistics

Total Valuation

Takeda Pharmaceutical Company has a market cap or net worth of GBP 34.65 billion. The enterprise value is 60.29 billion.

Market Cap	34.65B
Enterprise Value	60.29B

Important Dates

The last earnings date was Thursday, January 30, 2025.

Earnings Date	Jan 30, 2025
Ex-Dividend Date	Sep 30, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.17%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.58B

Valuation Ratios

The trailing PE ratio is 32.78.

PE Ratio	32.78
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.82, with an EV/FCF ratio of 12.94.

EV / Earnings	57.04
EV / Sales	2.54
EV / EBITDA	8.82
EV / EBIT	19.67
EV / FCF	12.94

Financial Position

The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.73.

Current Ratio	1.31
Quick Ratio	0.59
Debt / Equity	0.73
Debt / EBITDA	4.13
Debt / FCF	5.92
Interest Coverage	6.57

Financial Efficiency

Return on equity (ROE) is 2.94% and return on invested capital (ROIC) is 2.97%.

Return on Equity (ROE)	2.94%
Return on Assets (ROA)	2.51%
Return on Invested Capital (ROIC)	2.97%
Return on Capital Employed (ROCE)	4.53%
Revenue Per Employee	472,071
Profits Per Employee	21,450
Employee Count	49,281
Asset Turnover	0.31
Inventory Turnover	1.31

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.77% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-7.77%
50-Day Moving Average	13.34
200-Day Moving Average	13.68
Relative Strength Index (RSI)	54.14
Average Volume (20 Days)	2,122

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Takeda Pharmaceutical Company had revenue of GBP 23.26 billion and earned 1.06 billion in profits. Earnings per share was 0.66.

Revenue	23.26B
Gross Profit	15.21B
Operating Income	3.00B
Pretax Income	1.19B
Net Income	1.06B
EBITDA	6.42B
EBIT	3.00B
Earnings Per Share (EPS)	0.66

Full Income Statement

Balance Sheet

The company has 2.51 billion in cash and 27.59 billion in debt, giving a net cash position of -25.08 billion.

Cash & Cash Equivalents	2.51B
Total Debt	27.59B
Net Cash	-25.08B
Net Cash Per Share	n/a
Equity (Book Value)	37.69B
Book Value Per Share	23.78
Working Capital	3.33B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 5.66 billion and capital expenditures -998.53 million, giving a free cash flow of 4.66 billion.

Operating Cash Flow	5.66B
Capital Expenditures	-998.53M
Free Cash Flow	4.66B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 65.38%, with operating and profit margins of 12.88% and 4.54%.

Gross Margin	65.38%
Operating Margin	12.88%
Pretax Margin	5.13%
Profit Margin	4.54%
EBITDA Margin	27.62%
EBIT Margin	12.88%
FCF Margin	20.03%

Dividends & Yields

This stock pays an annual dividend of 0.41, which amounts to a dividend yield of 3.07%.

Dividend Per Share	0.41
Dividend Yield	3.07%
Dividend Growth (YoY)	-7.34%
Years of Dividend Growth	n/a
Payout Ratio	145.09%
Buyback Yield	-1.17%
Shareholder Yield	1.90%
Earnings Yield	3.05%
FCF Yield	13.45%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Takeda Pharmaceutical Company has an Altman Z-Score of 1.12. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.12
Piotroski F-Score	n/a